Eton Pharmaceuticals, Inc. Operating Lease, Expense
Eton Pharmaceuticals, Inc. (ETON) reported Operating Lease, Expense of $53.00 thousand for the 9-month period ending 2024-09-30, per its 10-Q filed 2024-11-12.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseExpense · last filed 2024-11-12
- Eton Pharmaceuticals, Inc. operating lease, expense for the quarter ending 2024-09-30 was $17.00K, a 54.55% increase year-over-year.
- Eton Pharmaceuticals, Inc. operating lease, expense for the quarter ending 2023-12-31 was $27.00K.
- Eton Pharmaceuticals, Inc. operating lease, expense for the quarter ending 2023-09-30 was $11.00K.
- Eton Pharmaceuticals, Inc. operating lease, expense for fiscal 2023 was $77.00K, a 10.47% decline from fiscal 2022.
- Eton Pharmaceuticals, Inc. operating lease, expense for fiscal 2022 was $86.00K, a 23.89% decline from fiscal 2021.
- Eton Pharmaceuticals, Inc. operating lease, expense for fiscal 2021 was $113.00K, a 18.71% decline from fiscal 2020.
- Eton Pharmaceuticals, Inc. operating lease, expense for fiscal 2020 was $139.00K, a 0.71% decline from fiscal 2019.
| Period end | Operating Lease, Expense 3 month | Operating Lease, Expense 6 month | Operating Lease, Expense 8 month | Operating Lease, Expense 9 month | Operating Lease, Expense 12 month | Operating Lease, Expense 12 month as first filed |
|---|---|---|---|---|---|---|
| 2024-09-30 | $17.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $53.00K 10-Q · filed 2024-11-12 | ||||
| 2024-06-30 | $36.00K 10-Q · filed 2024-08-08 | |||||
| 2023-12-31 | $27.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $38.00K derived: sum of 2 quarters · filed 2024-11-12 | $77.00K 10-K · filed 2024-03-14 | |||
| 2023-09-30 | $11.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $50.00K 10-Q · filed 2024-11-12 | ||||
| 2023-06-30 | $39.00K 10-Q · filed 2024-08-08 | |||||
| 2022-12-31 | $86.00K 10-K · filed 2024-03-14 | $87.00K 10-K · filed 2023-03-16 | ||||
| 2021-12-31 | $113.00K 10-K · filed 2024-03-14 | |||||
| 2020-12-31 | $139.00K 10-K · filed 2023-03-16 | |||||
| 2019-12-31 | $140.00K 10-K · filed 2022-03-16 | |||||
| 2018-12-31 | $115.00K 10-K · filed 2021-03-16 | |||||
| 2017-12-31 | $14.00K 10-K · filed 2020-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |